OTCQB: LXXGF | TSX.V: LXG

BioSpace article on LexaGene antibiotic resistance testing

by | Aug 7, 2019 | Biothreat Detection

Home » Biothreat Detection » BioSpace article on LexaGene antibiotic resistance testing

The CDC and FDA AR Isolate Bank will provide information to LexaGene which will support the company’s diagnostics development and help address the serious issue of antibiotic resistance.

Read More at BioSpace

<a href="https://lexagene.com/author/lexagene-admin/" target="_self">LexaGene</a>

LexaGene

LexaGene develops fully automated, rapid molecular testing at the point-of-need for accurate pathogen detection in human clinical diagnostics, veterinary diagnostics, food safety, and other markets.

Survey Says Veterinarians Have an Appetite for In-Clinic Diagnostic Technology

This spring LexaGene conducted a market research survey in conjunction with AAHA to assess the opinions of practicing veterinarians on AMR stewardship and the use of antibiotics in the treatment of companion animals.

Read More

The Dawn of the Superbugs

The most menacing of all resistant bacteria are the so called “super bugs”- strains of bacteria that are resistant to several different classes of antibiotics or multidrug resistant.

Read More

LexaGene offers North Shore Technology Council (NSTC) and Leadership Team at MassBio a tour of our Beverly Facility

Recently, we welcomed members of North Shore Technology Council and MassBio Leadership Teams into our facility at 500 Cummings Center for a full tour of our office space and laboratory spaces.

Read More
Subscribe for Updates

Upcoming Events

No events in this category to show at this time.

See All Events

Latest Resources

BioThreat Sell Sheet

MiQLab for Rapid Response to Novel Biothreats


LexaGene’s MiQLab™ System, a TRL-7 technology, drastically shortens the time gap between novel pathogen identification and point-of-need testing through its open-access feature.

See All Resources